Daiichi Sankyo, Lilly Drug At Top Of U.S. FDA List For Investigation
This article was originally published in PharmAsia News
Executive SummaryDaiichi Sankyo's and U.S. drug maker Eli Lilly's co-developed Effient (prasugrel) blood-thinner leads a U.S. FDA list of drugs on a schedule of planned investigations
You may also be interested in...
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.